JP2016516789A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516789A5 JP2016516789A5 JP2016508054A JP2016508054A JP2016516789A5 JP 2016516789 A5 JP2016516789 A5 JP 2016516789A5 JP 2016508054 A JP2016508054 A JP 2016508054A JP 2016508054 A JP2016508054 A JP 2016508054A JP 2016516789 A5 JP2016516789 A5 JP 2016516789A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptides
- antibody
- binding molecule
- cancer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 101710120463 Prostate stem cell antigen Proteins 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101150076616 EPHA2 gene Proteins 0.000 claims 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025538 Malignant ascites Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000004882 non-tumor cell Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13164555 | 2013-04-19 | ||
| EP13164555.8 | 2013-04-19 | ||
| PCT/EP2014/054390 WO2014170063A1 (en) | 2013-04-19 | 2014-03-06 | Novel bispecific binding molecules with antitumoral activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019013831A Division JP2019106997A (ja) | 2013-04-19 | 2019-01-30 | 抗腫瘍活性を有する新規な二重特異的結合分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516789A JP2016516789A (ja) | 2016-06-09 |
| JP2016516789A5 true JP2016516789A5 (cg-RX-API-DMAC7.html) | 2017-03-30 |
| JP6694808B2 JP6694808B2 (ja) | 2020-05-20 |
Family
ID=48128216
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016508054A Expired - Fee Related JP6694808B2 (ja) | 2013-04-19 | 2014-03-06 | 抗腫瘍活性を有する新規な二重特異的結合分子 |
| JP2019013831A Pending JP2019106997A (ja) | 2013-04-19 | 2019-01-30 | 抗腫瘍活性を有する新規な二重特異的結合分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019013831A Pending JP2019106997A (ja) | 2013-04-19 | 2019-01-30 | 抗腫瘍活性を有する新規な二重特異的結合分子 |
Country Status (15)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| BR112014030812B1 (pt) | 2012-06-13 | 2022-11-08 | Incyte Holdings Corporation | Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr |
| ME03015B (me) | 2013-04-19 | 2018-10-20 | Incyte Holdings Corp | Biciklični heterocikli kao fgfr inhibitori |
| PT3083689T (pt) | 2013-12-17 | 2020-08-27 | Genentech Inc | Anticorpos anti-cd3 e métodos de utilização |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| JP2018526972A (ja) | 2015-06-16 | 2018-09-20 | ジェネンテック， インコーポレイテッド | 抗ｃｄ３抗体及び使用方法 |
| FI126633B (en) | 2015-07-10 | 2017-03-15 | Next Biomed Therapies Oy | Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1) |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| US10722589B2 (en) * | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| JP2020517659A (ja) * | 2017-04-24 | 2020-06-18 | イクノス サイエンシズ エスエー | Ｅｇｆｒ陽性癌の治療のためのｔ細胞リダイレクト二重特異性抗体 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019033050A1 (en) * | 2017-08-11 | 2019-02-14 | City Of Hope | BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN |
| US11427826B2 (en) | 2017-08-11 | 2022-08-30 | City of Hopw | RNA aptamers against transferrin receptor (TfR) |
| CN111315773A (zh) * | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | 含有Fc区的条件性活化的结合部分 |
| IL317013A (en) | 2017-09-08 | 2025-01-01 | Takeda Pharmaceuticals Co | Binding proteins are activated under limited conditions |
| US20190100587A1 (en) * | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| SG11202007390YA (en) | 2018-02-08 | 2020-08-28 | Genentech Inc | Bispecific antigen-binding molecules and methods of use |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| US20210188990A1 (en) | 2019-12-11 | 2021-06-24 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| AU2020403145B2 (en) | 2019-12-13 | 2025-06-26 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| MX2023005130A (es) | 2020-11-04 | 2023-05-25 | Genentech Inc | Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3. |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN119013299A (zh) | 2022-04-13 | 2024-11-22 | 基因泰克公司 | 莫苏尼妥珠单抗的药物组合物及使用方法 |
| US20250295809A1 (en) | 2022-05-13 | 2025-09-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025221728A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| US9376477B2 (en) * | 2009-08-27 | 2016-06-28 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
| WO2011116387A1 (en) * | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| CN107253992B (zh) * | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
-
2014
- 2014-03-06 HK HK16102370.8A patent/HK1214605A1/zh unknown
- 2014-03-06 SG SG11201508231UA patent/SG11201508231UA/en unknown
- 2014-03-06 CA CA2908988A patent/CA2908988A1/en not_active Abandoned
- 2014-03-06 JP JP2016508054A patent/JP6694808B2/ja not_active Expired - Fee Related
- 2014-03-06 MX MX2015014608A patent/MX2015014608A/es unknown
- 2014-03-06 EP EP14710220.6A patent/EP2986630B1/en active Active
- 2014-03-06 KR KR1020157031680A patent/KR20160002882A/ko not_active Withdrawn
- 2014-03-06 CN CN201480022196.2A patent/CN105189544A/zh active Pending
- 2014-03-06 BR BR112015026143A patent/BR112015026143A2/pt not_active IP Right Cessation
- 2014-03-06 EA EA201592006A patent/EA201592006A1/ru unknown
- 2014-03-06 WO PCT/EP2014/054390 patent/WO2014170063A1/en not_active Ceased
- 2014-03-06 AU AU2014256037A patent/AU2014256037B2/en not_active Ceased
-
2015
- 2015-09-30 PH PH12015502278A patent/PH12015502278A1/en unknown
- 2015-10-16 ZA ZA2015/07752A patent/ZA201507752B/en unknown
- 2015-10-19 CL CL2015003085A patent/CL2015003085A1/es unknown
-
2019
- 2019-01-30 JP JP2019013831A patent/JP2019106997A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516789A5 (cg-RX-API-DMAC7.html) | ||
| JP2015516801A5 (cg-RX-API-DMAC7.html) | ||
| RU2509085C2 (ru) | Стабилизированные антитела против ангиопоэтина-2 и их применение | |
| NZ708182A (en) | Bispecific t cell activating antigen binding molecules | |
| AU2018264321A1 (en) | Bispecific recombinant protein and use thereof | |
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| MX2015014608A (es) | Novedosas moleculas de union biespecifica con actividad antitumoral. | |
| DOP2019000011A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| FI3227342T4 (fi) | Proteiininen heterodimeeri ja sen käyttö | |
| JP2018512168A5 (cg-RX-API-DMAC7.html) | ||
| HRP20150300T4 (hr) | Novi i snažni mhc-razred ii peptidi derivirani iz survivina i neurokana | |
| MX2010004910A (es) | Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico. | |
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| AR104114A1 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
| JP2014088414A5 (cg-RX-API-DMAC7.html) | ||
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| RU2017108203A (ru) | Слитые белки sirp-альфа с иммуноглобулином | |
| JP2013166763A5 (cg-RX-API-DMAC7.html) | ||
| MX2011009810A (es) | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| JP2014518615A5 (cg-RX-API-DMAC7.html) | ||
| JP2017525698A5 (cg-RX-API-DMAC7.html) | ||
| NZ583282A (en) | Human c-fms antigen binding proteins |